Robert Iannone sold $981k of JAZZ
EVP, Global Head of R&D & CMO at Jazz Pharmaceuticals plc. 7,080 shares at an average of $138.60, traded Mar 7, 2025, filed Mar 7, 2025.
Score components
- +15RoleOfficer
- +25Trade size$981k at market
- 0Share of holdings soldSold 7.9% of holdings
- +15Cluster4 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -20.7%, 3m -19.9%, 6m -6.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001765581-25-000026, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 5, 2025 | DDisposition to issuer Ordinary Shares10b5-1 | -5,239 | $138.95 | $728k | 89,104 | Mar 7, 2025 |
| Mar 7, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -5,532 | $138.21 | $765k | 83,572 | Mar 7, 2025 |
| Mar 7, 2025 | SOpen-market sale Ordinary Shares10b5-1 | -1,548 | $140.00 | $217k | 82,024 | Mar 7, 2025 |
Related signals
Other insiders at Jazz Pharmaceuticals plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Jazz Pharmaceuticals plc | Renee D Gala President & CEO | $473k 2,000 shares | -1% | |
| 28Weak | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $1.4M 6,000 shares | -2% | |
| 24Weak | Jazz Pharmaceuticals plc | Neena M Patil EVP & Chief Legal Officer | $289k 1,200 shares | -2% | |
| 38Weak | Jazz Pharmaceuticals plc | Renee D Gala President & CEO | $486k 2,000 shares | -1% | |
| 45Moderate | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $1.5M 6,000 shares | -2% | |
| 40Moderate | Jazz Pharmaceuticals plc | Robert Iannone EVP, Global Head of R&D & CMO | $19M 76,921 shares | -54% | |
| 20Weak | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $1.5M 6,000 shares | -2% | |
| 20Weak | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $1.4M 6,000 shares | -2% | |
| 28Weak | Jazz Pharmaceuticals plc | Mark Douglas Smith director | $267k 1,157 shares | -11% | |
| 24Weak | Jazz Pharmaceuticals plc | Neena M Patil EVP & Chief Legal Officer | $278k 1,200 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.